Skip to main content
Jatin Shah, MD, Oncology, Houston, TX

JatinShahMD

Oncology • Houston, TX

Associate Professor

Join to view full profile

Dr. Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shah's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2001

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2007 - 2025

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
    Jatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Jatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
    Jatin J. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual Meeting
    Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual MeetingDecember 9th, 2024
  • Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing Sarcoma
    Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing SarcomaApril 10th, 2023
  • Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
    Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of MyelofibrosisJune 8th, 2022
  • Join now to see all

Dr. Jatin Shah, Dr. Jatin Shah, MD, Dr. J Shah